Oxular Acquisitions Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Kinase inhibitors (US 10,301,288) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Kinase Inhibitors (US 10,392,346) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 2 fees due Apr 8 to 15, 2027 · next Apr 8
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,301,288 | Kinase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,927,563 | Kinase Inhibitor In force · High confidence | In force | High confidence | |
| US 10,435,361 | Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,392,346 | Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,442,828 | Kinase Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 15 lapsed for an unpaid fee · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.